H2020Индивидуална стипендия2021–2023

SMD-SPH · Development of scalable microfluidic device for drug testing using humanized adipose tissue spheroids

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-12-01 → 2023-11-30
Финансиране от ЕС: 196 708 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Микрофлуидни биореактори се разработват за масово производство на 3D модели от човешка мастна тъкан. Тези системи помагат за по-точно тестване на лекарства и намаляване на опитите върху животни.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Development of scalable microfluidic device for drug testing using humanized adipose tissue spheroids

In regenerative medicine, advanced therapeutic products derived from tissue engineering technologies and are critical for more accurate medical innovation. Tissue engineered scaffold-free 3D models, including organoids, exhibit functional hallmarks of human native tissues improving the search for biomarkers, drug testing/development and toxicology models, while supporting the development of alternative methods to animal use, as stated by the Directive (2010/63/ EU) established the European Centre for the validation of alternative methods (ECVAM). To replace animal testing, it is important to develop microphysiological systems and ‘body-on-chip’ approaches at a reasonable cost. Yet, most current bioreactors in tissue engineering are expensive, designed for organ transplant and poorly designed for miniaturization and scale-up. Furthermore, organoid production faces critical challenges such as small-scale, high costs and reproducibility. Currently, the scientific literature has been arguing that the convergence of organoids and microfluidic technologies to overcome these limitations. Specifically, microfluidics technologies can work as bioreactors, reducing labor hours and cost by supporting automated systems and low volume of reagents. The main objective of this study was to develop a microfluidic bioreactor for organoid mass production. To reached this, we accomplish the following specific objectives: - a bioreactor design containing hundreds of individual chambers for organoids; - 3D simulations to analyze the microfluidic flow and the nutrients reaching the organoids inside the individual chambers; - microfabrication of the bioreactor prototype based on hot embossing technology (Sublym) using a biocompatible polymer (Flexdym). Sublym and Flexdym are registered technologies from Eden Tech. - seeding of human adipose-tissue derived stem/stromal cells (ASCs) in the microchannels of the bioreactor to form individual organoids inside each individual chamber; - viability and adipogenesis assays to attest the functionality of ASC organoids.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

In regenerative medicine, in vitro tissue engineering products (3D cell cultures) for in vivo therapy are critical for more accurate and more humane medical innovation. Tissue engineered scaffold-free 3D models that exhibit functional hallmarks of native tissues improve our search for biomarkers, drug testing/development and toxicology with more accurate models, while supporting the development of alternative methods to animal use in drug testing, as stated by the Directive (2010/63/EU) established the European Centre for the validation of alternative methods (ECVAM). To replace animal testing, it is important to develop microphysiological systems and ‘body-on-chip’ approaches that allow to account for organ-to-organ interactions in vitro, at a reasonable cost. Yet, most current bioreactors are expensive, designed for organ transplant (thus focused on a single organ) and poorly designed for miniaturization and scale-up. In SMD-SPH, we will develop a microphysiological systems with the following design requirement: a 3D cell culture model, with a continuous and controllable perfusion system for continuous contact with morphogens (growth factors) to obtain a functional native tissue and monitoring crucial parameters of cell physiology, compatible with scale-up manufacturing. To the best of our knowledge, it is the first time in scientific literature that human adipose tissue-derived stem cells are used to build human white adipose tissue in a novel and scalable microphysiological system. This project meets the convergence of microfluidics and scaffold-free 3D culture models offering a reliable alternative for drug and toxicology assays, besides offer a scalable and reproductible system for future integration into a human-on-a-chip and high-troughput assays. Once an initial prototype is obtained, we will start dissemination to stakeholders and seek early adopters, cosmetic industries.

Оригинален текст от CORDIS (на английски).

Участници

EDEN TECH · ParisКоординаторФранция